Melanoma

M-Vax Reported to Prolong Survival in Resected Stage IV Patients

Published in Vaccine Weekly, December 6th, 2000

Avax Technologies, Inc. (AVXT), Kansas City, Missouri, announced that data relating to M-Vax, its proprietary autologous cell vaccine for melanoma, were presented at the 18th Chemotherapy Foundation Symposium "Innovative Cancer Therapy for Tomorrow" during November 2000.

In an invited presentation entitled "Autologous, hapten-modified vaccine in melanoma and other solid tumors," David Berd, MD, Thomas Jefferson University, Philadelphia, Pennsylvania, summarized results of trials in which M-Vax was administered to 37 stage IV melanoma patients who had undergone complete resection of metastatic tumors that had spread to various internal organs.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry